Language：English   Publishing type：Research paper (scientific journal)  

PURPOSE: We aimed to compare the efficacy of the VIO soft coagulation system (VSCS) for the treatment of air leaks by sealing with fibrin glue, and also assess the histological alterations that occur after soft coagulation. METHODS: A mouse pulmonary air leak model was designed. The pulmonary fistula was subsequently coagulated with the VSCS or sealed with fibrin glue with polyglycolic acid (PGA) sheets. The burst pressure at air leak recurrence was measured in each group, and the results were compared. We also evaluated the histological alterations in the mouse pulmonary air leak model after soft coagulation with the VSCS. RESULTS: The burst pressure in the soft coagulation group (80 W/Effect 5) (median 42.8; range 35.4-53.8 cmH2O) was similar to that in the fibrin glue group (median 41.5; range 34.6-43.9 cmH2O) (p = 0.21). Histological examinations revealed that the visceral pleura remained torn, the structure of the pulmonary alveolus was maintained, and the coagulated fistula was covered with a fibrin membrane in the soft coagulation group. CONCLUSIONS: The pressure resistance following soft coagulation was equivalent to that after sealing using fibrin glue with PGA sheets. The air leaks were likely controlled by covering the fistula with a fibrin membrane after soft coagulation with the VSCS.

DOI： 10.1007/s00595-021-02251-3

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: The objective of this study was to analyze the efficacy of the LigaSureTM vessel sealing system for lung cancer resection with node dissection, as this has not been sufficiently evaluated. METHODS: From 2004 to 2018, 948 patients underwent anatomical pulmonary resection with node dissection for non-small cell lung carcinoma (NSCLC) via the video-assisted thoracoscopic surgery (VATS) approach. Medical records of these patients were reviewed retrospectively. Univariate and multivariate analyses were conducted to determine the risk factors for chylothorax and blood loss. RESULTS: Of the 948 patients, 318 (33.5%) who underwent anatomical lung resection with node dissection by conventional methods without vessel sealing system and 630 (66.5%) who underwent lung resection with node dissection with the vessel sealing system were included. The median intraoperative blood loss was 100 mL. Postoperative chylothorax occurred in 9 (2.8%) patients in the conventional method group with 2 (0.3%) patients in the vessel sealing system group (P=0.001). Patients in the vessel sealing group who developed chylothorax were cured by conservative treatment. Univariate and multivariate analyses identified male sex [odds ratio (OR) 2.053; 95% confidence interval (CI): 1.494-2.820; P<0.001] and the use of vessel sealing system (OR 0.342; 95% CI: 0.256-0.457; P<0.001) as independent predictors of intraoperative blood loss. The univariate and multivariate analyses identified the use of the vessel sealing system (OR 0.108; 95% CI: 0.023-0.504; P=0.005) as an independent predictor of chylothorax incidence. CONCLUSIONS: Vessel sealing system for lung cancer resection could decrease chest tube duration, amount of intraoperative bleeding, and incidence of chylothorax in patients who undergo lung resection with node dissection.

DOI： 10.21037/jtd-21-169

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

Ichushi

researchmap

Language：English  

Interstitial lung disease (ILD) is a common complication of systemic sclerosis (SSc). Nintedanib, an antifibrotic drug, has recently been approved for treating SSc-ILD. Although there have been no reports suggesting the development of pneumothorax with nintedanib use, its safety in patients with impaired lung function is unclear. We observed the development of refractory spontaneous pneumothorax during nintedanib therapy in two patients with SSc-ILD and impaired lung function. Nintedanib use for SSc-ILD, an extensive disease, may therefore increase the risk of pneumothorax. In addition, pneumothorax is more likely to be refractory in these cases; initiation of nintedanib treatment and follow-up should be considered carefully.

DOI： 10.1002/rcr2.716

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: The movement of a double-lumen endotracheal tube (DLT) out of its appropriate position during thoracic surgery can result in the loss of one-lung ventilation (OLV), especially during pulmonary resection and node dissection. Our study aimed to validate the efficacy of automatic retention pressure control of the DLT bronchial cuff in maintaining OLV in an artificial intubation model. MATERIALS AND METHODS: A 35-Fr left-sided DLT was intubated to the left main bronchus in an intubation simulator and connected to an anesthesia machine. The inspiratory volume, respiratory rate, and inspiratory-expiratory ratio were set at 500 mL, 12 times/min, and 1:2, respectively. A 1-kg right main bronchial traction in the lateral right was provided after OLV was established. SmartCuff (Smiths Medical, Minneapolis, Minnesota, USA) was used to maintain cuff pressure. The efficacy of retention pressure with SmartCuff (Group S) and without SmartCuff (Group WS) was compared. The primary outcome was the rate of tidal volume (TV) reduction following bronchial traction in the two groups. RESULTS: The TVs were 289.8 ± 28.9 mL and 242.8 ± 31.9 mL in Group S and Group WS, respectively (P = 0.003). The rate of TV reduction after bronchial traction was significantly lower in Group S (29 ± 5%) than in Group WS (43 ± 6%) (P < 0.001). CONCLUSIONS: Automatic retention pressure control of the DLT bronchial cuff improves the rate of TV reduction during right main bronchial traction in an artificial intubation model. Continuous retention cuff pressure may be useful in maintaining OLV during thoracic surgery.

DOI： 10.1016/j.jss.2020.08.017

PubMed

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

Language：English  

A clinical trial of immune checkpoint inhibitors for advanced non-small cell lung cancer reported an overall survival plateau with a long tail to the survival curve, suggesting that immune checkpoint inhibitors prolong survival. However, little evidence supports the efficacy of immune checkpoint inhibitors as neoadjuvant chemotherapy. We performed salvage surgery on a patient who was treated with an anti-programmed cell death protein-1 (PD-1) antibody and whose tumor size had not changed over time. A 69-year-old Japanese female with advanced lung adenocarcinoma was initially administered pembrolizumab therapy; however, owing to the development of various immune-related adverse events (irAEs), the patient was switched to chemotherapy following steroid therapy. The tumor continued to shrink and calcification within the tumor increased. We performed salvage surgery following which the tumor cells disappeared and necrosis and calcification were detected in the tumor. We concluded that if calcification develops within the tumor and tumor shrinkage is maintained after treatment with anti-PD-1 drugs, the calcification may be dystrophic owing to drug-induced tumor necrosis, and salvage surgery might be beneficial in removing the tumor. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: If calcification develops within the tumor and tumor shrinkage is maintained after treatment with anti-PD-1 drugs, the calcification may be dystrophic owing to tumor necrosis caused by drug effects, and salvage surgery might be beneficial in removing the tumor. WHAT THIS STUDY ADDS: This study showed the efficacy of immune checkpoint inhibitors as neoadjuvant chemotherapy to be followed by salvage surgery for unresectable advanced lung adenocarcinoma.

DOI： 10.1111/1759-7714.13663

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

PURPOSE: To identify and clarify the comprehensive anatomic patterns in the left lower lobe (LLL). METHODS: Using computed tomography (CT) imaging data, including that obtained using three-dimensional CT, we reviewed the anatomic patterns of the pulmonary vessels and bronchi in the left lungs of 539 patients, focusing on the LLL. RESULTS: The two-stem type in A6 was observed in 131 (24.7%) patients and the three-stem type in A6 was observed in 11 (2.1%) patients. The independent two-stem type in B6 was observed in four (0.75%) patients. The B7 with independent branching from the basal bronchi was observed in 42 (7.9%) patients. B* was observed in 129 (24.0%) patients and B* was accompanied by A* in all patients. An extrapericardial common trunk of the left pulmonary veins was identified in five patients (0.93%). CONCLUSION: We identified various bronchovascular patterns in the LLL of a large number of patients. Our results provide useful information for anatomic pulmonary resection, especially segmentectomy.

DOI： 10.1007/s00595-020-01991-y

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease that includes fibroblastic foci (FF). It has been increasingly appreciated that the origin of collagen-overproducing cells such as pathological myofibroblasts in FF is pericytes. However, neither pericytes derived from the lung nor FF in the IPF lung have not been fully characterized. Human lung pericytes (HuL-P) examined in this study expressed two representative pericyte markers; platelet-derived growth factor receptor β (PDGFRB) and chondroitin sulfate proteoglycan 4 (CSPG4), and were able to migrate and cover endothelial tubes in 3D conditions, indicating that they retain characteristics of pericytes. Moreover HuL-P cells transitioned to myofibroblast-like cells in the presence of transforming growth factor (TGF)-β signaling or to pericyte-like cells in the absence of TGF-β signaling (pericyte-myofibroblast transition). On the other hand, the FF detected in this study were invariably localized between peripheral lung epithelia and capillary endothelia, the basement membranes of which are physiologically fused. The localization is highly specific in that the only cells that exist between the gap are pericytes. As expected, FF were immunohistochemically positive for PDGFRB and CSPG4, suggesting that pericytes are activated to form FF. We also found that HuL-P cells were difficult to eradicate by dual silencing of Bcl-xL plus MCL1. It would be more sensible to suppress pericyte-myofibroblast transition than to kill activated myofibroblasts for the treatment of IPF.

DOI： 10.1016/j.bbrc.2020.05.091

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Although most EGFR-mutant lung adenocarcinomas initially respond to EGFR inhibitors, disease progression almost inevitably occurs. We previously reported that two EGFR-mutant lung adenocarcinoma cell lines, HCC827 and H1975, contain subpopulations of cells that display an epithelial-to-mesenchymal phenotype and can thrive independently of EGFR signaling. In this study, we explored to what extent these two sublines, HCC827 GR2 and H1975 WR7, depended on the anti-apoptotic BCL2 family members, Bcl-xL and/or MCL1, for survival. Although HCC827 GR2 cells were hardly affected by Bcl-xL or MCL1 knockdown alone, dual inhibition of Bcl-xL and MCL1 caused the cells to undergo apoptosis, resulting in decreased viability. In H1975 WR7 cells, not only dual inhibition, but also MCL1 silencing alone, induced the cells to undergo apoptosis. Interestingly, the two sublines markedly declined in number when autophagy flux was suppressed, because they depend, in part, on active autophagy for survival. However, autophagy inhibition was inferior to dual inhibition of Bcl-xL plus MCL1 for GR2 cells, or MCL1 inhibition alone, for decreasing the viability of WR7 cells. Collectively, these findings suggest that inhibiting Bcl-xL plus MCL1, or MCL1 alone, may represent a new approach to treat EGFR-independent EGFR-mutant cancer cells.

DOI： 10.1016/j.bbrc.2020.03.116

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Thrombus of the pulmonary vein (PV) stump is reportedly more frequent after left upper lobectomy than after other lobectomies, risking postoperative cerebral infarction (PCI). We have performed central vascular ligation before vascular dissection to improve the safety of surgical stapling. The effects of central vascular ligation in terms of PV stump thrombus and PCI are uncertain. METHODS: This study retrospectively reviewed the records of patients who underwent left upper lobectomy at a single center (Hokkaido Cancer Center, Sapporo, Japan) between November 1, 2008 and July 31, 2018. Relationships between PCI, PV stump thrombus and background characteristics were investigated and analyzed. RESULTS: All 208 cases of left upper lobectomy underwent central vascular ligation of the PV during this study. PCI occurred in 8 of the 208 patients. PV stump thrombus was detected in 14 of the 132 patients. In comparison with no-PCI cases, PCI cases showed significantly higher rates of comorbidity with cardiovascular disease (P=0.02), double cancer within 5 years (P=0.04), intraoperative hyperthermic chemotherapy (P=0.02), postoperative intrapleural inflammation (P=0.02) and postoperative PV stump thrombus (P=0.04). Presence of both comorbid cardiovascular disease (odds ratio, 18.4) and intraoperative hyperthermic chemotherapy (odds ratio, 30.4) was associated with higher risk of PV stump thrombus than presence of none of these factors. Cerebral infarction within 30 days postoperatively was seen in only 2 of the 208 cases (1.0%). CONCLUSIONS: Central ligation of the PV may prevent postoperative early cerebral infarction. Further study of the effectiveness of this method for preventing PV stump thrombus is needed.

DOI： 10.21037/jtd.2020.04.02

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

OBJECTIVES: MCL1 is an anti-apoptotic BCL2 family member that is highly expressed in various malignant tumors. However, little is known about the role of MCL1 in KRAS-mutant lung adenocarcinomas. In this study, we aimed to clarify whether MCL1 could be a therapeutic target in KRAS-mutant lung adenocarcinomas for which no effective molecular targeted drugs are available. MATERIALS AND METHODS: We examined to what extent MCL1 knockdown either alone or in combination with MEK inhibitor trametinib suppressed growth or induced apoptosis in the KRAS-mutant lung adenocarcinoma cell line H441 and EGFR-mutant lung adenocarcinoma cell line H1975. Furthermore, we investigated the therapeutic effects of dual inhibition of MCL1 and Bcl-xL, another anti-apoptotic BCL2 family member, in these two cell lines. RESULTS: MCL1 knockdown alone did not induce apoptosis in H441 or H1975 cells. However, MCL1-depleted H441 and H1975 cells underwent apoptosis and decreased in number in the presence of trametinib. We also confirmed that combined therapy by MCL1 knockdown and trametinib almost completely suppressed the growth of H441 cells in vivo. Moreover, dual knockdown of MCL1 and Bcl-xL induced extensive apoptosis in H441 and H1975 cells. CONCLUSION: These findings suggest that combined treatments of MCL1 knockdown and trametinib or dual inhibition of MCL1 and Bcl-xL would be effective therapies for lung adenocarcinomas including the KRAS-mutant subtype.

DOI： 10.1016/j.lungcan.2019.05.014

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Completion lobectomy long after segmentectomy in the same lobe is extremely difficult because of severe adhesions around hilar structures, especially in cases involving video-assisted thoracoscopic surgery (VATS) completion lobectomy. We report and compare the surgical outcomes of patients who underwent VATS or thoracotomy completion lobectomy long after radical segmentectomy for lung cancer. METHODS: We retrospectively evaluated the surgical outcomes of completion lobectomies performed at our institute long after radical segmentectomies for lung cancer in the same lobe. The efficacy and safety of VATS completion lobectomy was compared to that of thoracotomy completion lobectomy. RESULTS: Ten of 228 patients who underwent radical segmentectomy for lung cancer between 2009 and 2018 underwent completion lobectomy at least a month after segmentectomy; five patients underwent VATS completion lobectomy. None of the patients underwent VATS left upper completion lobectomy, and conversion to thoracotomy was required in one patient. There were no significant differences between VATS and thoracotomy completion lobectomies in the median operative times (VATS 295 min, thoracotomy 339 min, p = 0.55), intraoperative blood loss volumes (VATS 350 mL, thoracotomy 500 mL, p = 0.84), intervals between initial segmentectomy and completion lobectomy (VATS 40 months, thoracotomy 48 months, p = 0.55), and number of patients with pulmonary artery injury (VATS 1, thoracotomy 2, p = 0.49). There was no operation-related mortality. CONCLUSIONS: VATS completion lobectomy long after segmentectomy for lung cancer could be performed without fatal complications unless severe adhesions are observed around each main pulmonary artery.

DOI： 10.1186/s13019-019-0941-8

PubMed

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)  

Paraffin had been used for pleural plombage in the treatment of tuberculosis. However, paraffin use has been reported to cause late postoperative complications. A 79-year-old man was presented with an extramedullary tumor and spinal paralysis. Forty-seven years ago, he had undergone pleural plombage using paraffin for the treatment of pulmonary tuberculosis. Since the extramedullary tumor was found to be paraffinoma, paraffin in the vertebral canal and thoracic cavity was removed surgically. All the paraffin in the vertebral canal and thoracic cavity was removed. After surgery, the patient remains well, without spinal paralysis.

PubMed

J-GLOBAL

researchmap

Language：Japanese  

A 46-year-old woman with cervical cancer with multiorgan metastasis visited our hospital. She underwent a total gastrectomy, splenectomy, distal pancreatectomy, left adrenalectomy, and left partial diaphragmatic resection. Postoperatively, she developed pleural effusion with high level of amylase secondary to a pancreatic fistula, consequently causing left-sided empyema. She developed acute respiratory distress syndrome. Urgent surgical treatment was scheduled, and left lower lobectomy, with diaphragmatic partial resection were performed under the venovenous extracorporeal membrane oxygenation. After surgery, intensive care for 45 days was necessary and she was discharged home 6 months post operatively.

PubMed

J-GLOBAL

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

This report describes a case of thoracoscopic right basilar segmentectomy after upper lobectomy. A 76-year-old man who underwent right upper lobectomy for lung tuberculosis 50 years earlier had a diagnosis of squamous cell carcinoma, stage IB (T2a N0 M0), in the right lower lobe and underwent right basilar segmentectomy for limited resection. The postoperative course was uneventful. The patient showed no recurrence clinically, and the 1-year postoperative chest computed tomographic scan showed adequate volume of the middle and residual right lower lobe without emphysematous changes.

DOI： 10.1016/j.athoracsur.2018.06.041

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Distal airway stem cells (DASCs) in the mouse lung can differentiate into bronchioles and alveoli. However, it remains unclear whether the same stem cells exist in the human lung. Here, we found that human lung epithelial (HuL) cells, derived from normal, peripheral lung tissue, in monolayer, mostly express both the N-terminally truncated isoform of p63 (∆Np63), a marker for airway basal cells, and thyroid transcription factor-1 (TTF-1), a marker for alveolar epithelial cells, even though these two molecules are usually expressed in a mutually exclusive way. Three-dimensionally cultured HuL cells differentiated to form bronchiole-like and alveolus-like organoids. We also uncovered a few bronchiolar epithelial cells expressing both ∆Np63 and TTF-1 in the human lung, suggesting that these cells are the cells of origin for HuL cells. Taken together, ΔNp63+ TTF-1+ peripheral airway epithelial cells are possibly the human counterpart of mouse DASCs and may offer potential for future regenerative medicine.

DOI： 10.1016/j.yexcr.2018.09.020

PubMed

researchmap

Language：Japanese   Publisher：The Japan Lung Cancer Society  

<b><i>Background. </i></b>Few reports have described the outcomes of three-time lung resection for metachronous multiple lung cancers or anatomical lung resection after pneumonectomy. <b><i>Case. </i></b>A 66-year-old man with a nodule in the left lung was treated with left upper lobectomy at 50 years of age and left lower lobectomy at 61 years of age. In both cases, the pathological diagnosis was minimally invasive adenocarcinoma, stage IA1. He visited our hospital for the further examination of an abnormal chest shadow noted at a medical checkup. The preoperative residual pulmonary function was as follows: VC 2.32 <i>l</i>, %VC 70.7%, FEV_1.0 1.59 <i>l</i>, and FEV_1.0% 70.1%. Although there was no definitive diagnosis, computed tomography revealed findings suggestive of primary lung cancer. He underwent superior segmentectomy (segment 6) of the right lower lobe with extracorporeal lung assist (ECLA). The postoperative course was uneventful. He was discharged home 14 days after the surgery. The pathological diagnosis was still adenocarcinoma <i>in situ</i>. <b><i>Conclusion. </i></b>Using ECLA, we were able to perform thoracoscopic segmentectomy for a metachronous multiple lung cancers (metachronous triple cancers) safely after pneumonectomy.

Other Link： https://search.jamas.or.jp/link/ui/2019010655

DOI： 10.2482/haigan.58.298

DOI： 10.2995/jacsurg.34.746_references_DOI_YSb6HuZxGp1gacqXpWN5ICzLTq3

CiNii Research

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Combined resection of a phrenic nerve is occasionally required in T3 primary lung carcinomas invading the phrenic nerve to completely remove a malignant tumour, resulting in diaphragmatic paralysis. We describe the first case of thoracoscopic lobectomy and diaphragmatic plication as a one-stage surgery for lung cancer invading the phrenic nerve. CASE PRESENTATION: A 56-year-old woman with a T3N0M0 primary adenosquamous carcinoma in the left upper lobe presented with suspicious invasion to the anterior mediastinal fat tissue and left phrenic nerve and underwent left upper lobectomy, node dissection, and partial resection of the anterior mediastinal fat tissue with the left phrenic nerve. Furthermore, thoracoscopic diaphragmatic plication was performed as a concomitant procedure. The patient's postoperative course was favourable, without any complications, and respiratory function was preserved for 1 year postoperatively. CONCLUSIONS: Thoracoscopic one-stage lobectomy and diaphragmatic plication for T3 lung cancer invading the phrenic nerve is effective for preservation of postoperative pulmonary function.

DOI： 10.1186/s13019-018-0766-x

PubMed

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)  

Immunohistochemical staining is important for the differential diagnosis of basaloid squamous cell carcinoma(BSC)and other similar carcinomas, such as small-cell carcinomas and large-cell neuroendocrine carcinomas. p40 is a useful marker of squamous cell carcinoma that can be used for the diagnosis of BSC. We present the case of a 64-year-old man who was referred to our hospital for investigation of an abnormal shadow revealed on chest radiography. Computed tomography(CT) revealed a 16×11 mm nodule in the left lung(S1+2), and a thoracoscopic left upper lobectomy was performed. Histologically, lobular pattern with peripheral palisading was observed and the immunohistochemical staining revealed the tumor cells to be positive for p63 and negative for both p40 and neuroendocrine markers, leading to the diagnosis of BSC.

PubMed

J-GLOBAL

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Survivin plays a key role in regulating the cell cycle and apoptosis, and is highly expressed in the majority of malignant tumors. However, little is known about the roles of survivin in KRAS-mutant lung adenocarcinomas. In the present study, we examined 28 KRAS-mutant lung adenocarcinoma tissues and two KRAS-mutant lung adenocarcinoma cell lines, H358 and H441, in order to elucidate the potential of survivin as a therapeutic target. We found that 19 (68%) of the 28 KRAS-mutant lung adenocarcinomas were differentiated tumors expressing thyroid transcription factor‑1 (TTF‑1) and E-cadherin. Patients with tumors immunohistochemically positive for survivin (n=18) had poorer outcomes than those with survivin-negative tumors (n=10). In the H358 and H441 cells, which expressed TTF‑1 and E-cadherin, survivin knockdown alone induced senescence, not apoptosis. However, in monolayer culture, the H358 cells and H441 cells in which survivin was silenced, underwent significant apoptosis following combined treatment with ABT-263, a Bcl‑2 inhibitor, and trametinib, a MEK inhibitor. Importantly, the triple combination of survivin knockdown with ABT-263 and trametinib treatment, clearly induced cell death in a three-dimensional cell culture model and in an in vivo tumor xenograft model. We also observed that the growth of the H358 and H441 cells was slightly, yet significantly suppressed in vitro when TTF‑1 was silenced. These findings collectively suggest that the triple combination of survivin knockdown with ABT-263 and trametinib treatment, may be a potential strategy for the treatment of KRAS-mutant lung adenocarcinoma. Furthermore, our findings indicate that the well‑differentiated type of KRAS-mutant lung tumors depends, at least in part, on TTF‑1 for growth.

DOI： 10.3892/ijo.2018.4365

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

High expression levels of survivin in KRAS-mutant lung adenocarcinomas are linked with unfavorable patient outcomes, suggesting that survivin is a promising target for tumor treatment. We found that trametinib, a MEK inhibitor, downregulates survivin expression in the RB1-positive KRAS-mutant lung adenocarcinoma cell lines H358 and H441. In these cell lines, trametinib treatment induced p21 expression and dephosphorylated RB1, leading to sustained suppression of survivin. Knockdown of p21 or RB1 restored survivin expression in trametinib-treated cells, at least partially, which supports the contribution of these molecules to trametinib-mediated survivin suppression. In RB1-negative KRAS-mutant lung adenocarcinoma H2009 cells, survivin downregulation by trametinib was only slight and transient, and trametinib-resistant (TR) cells developed within 1 month of treatment. H2009 TR cells depended much more on survivin for survival than its parental cells, as evidenced by apoptosis induction when survivin was depleted. These findings collectively suggest that trametinib is effective for the treatment of RB1-positive KRAS-mutant lung adenocarcinomas through sustained survivin suppression, but not for RB1-negative lung adenocarcinomas. Thus, the RB1 status could be a biomarker for trametinib application in KRAS-mutant lung adenocarcinomas.

DOI： 10.1016/j.bbrc.2018.04.230

PubMed

researchmap

J-GLOBAL

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

PURPOSE: Mediastinal node dissection (MND) is an integral component of the surgical treatment for non-small cell lung cancer (NSCLC). Although video-assisted thoracoscopic surgery (VATS) has been used increasingly for lung cancer treatment, the accuracy of by VATS MND still remains controversial. We reviewed the surgical results of VATS MND for NSCLC. METHODS: A systematic review of literature was performed, and articles that fully described the surgical procedure, devices, and results of VATS MND were selected to compare the efficacy of MND by VATS and thoracotomy. RESULTS: Various techniques and equipments have been shown to perform adequate MND, but there is an argument as to the method of estimation of the accuracy of MND. Most of the recent studies showed that the nodal upstaging and number of dissected nodes are significantly lower by VATS than after thoracotomy. Oppositely, some studies showed VATS noninferiority in these issues. Complications such as chylothorax, pleural effusion, bleeding, and nerve damage were similar in both groups. CONCLUSIONS: Although ND by VATS remains controversial, VATS MND is becoming easier and more feasible owing to the development of more advanced endoscopic cameras and equipments. We should learn further to become more adept at performing adequate ND by VATS.

DOI： 10.1007/s00595-017-1494-x

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

EGFR-mutant lung adenocarcinomas contain a subpopulation of cells that have undergone epithelial-to-mesenchymal transition and can grow independently of EGFR. To kill these cancer cells, we need a novel therapeutic approach other than EGFR inhibitors. If a molecule is specifically expressed on the cell surface of such EGFR-independent EGFR-mutant cancer cells, it can be a therapeutic target. We found that a mesenchymal EGFR-independent subline derived from HCC827 cells, an EGFR-mutant lung adenocarcinoma cell line, expressed angiotensin-converting enzyme 2 (ACE2) to a greater extent than its parental cells. ACE2 was also expressed at least partially in most of the primary EGFR-mutant lung adenocarcinomas examined, and the ACE2 expression level in the cancer cells was much higher than that in normal lung epithelial cells. In addition, we developed an anti-ACE2 mouse monoclonal antibody (mAb), termed H8R64, that was internalized by ACE2-expressing cells. If an antibody-drug conjugate consisting of a humanized mAb based on H8R64 and a potent anticancer drug were produced, it could be effective for the treatment of EGFR-mutant lung adenocarcinomas.

DOI： 10.1016/j.bbrc.2017.04.102

PubMed

researchmap

J-GLOBAL

researchmap

Language：Japanese   Publisher：The Japan Lung Cancer Society  

<b><i>Background. </i></b>There are still few reports of tracheal sleeve resection and reconstruction in elderly patients. <b><i>Case. </i></b>An 84-year-old woman was referred to our hospital with a diagnosis of tracheal adenoid cystic carcinoma, which was revealed by a transbronchial biopsy. Chest computed tomography (CT) revealed a tumor in the anterior wall of the thoracic trachea. We performed tracheal sleeve resection and reconstruction through median sternotomy. The postoperative course was uneventful. The patient was discharged from the hospital and allowed to return home 33 days after the surgery. <b><i>Conclusion. </i></b>A female octogenarian patient with tracheal adenoid cystic carcinoma was successfully treated with tracheal sleeve resection and has been well for 12 months without any signs of recurrence.

Other Link： https://search.jamas.or.jp/link/ui/2018135703

DOI： 10.2482/haigan.57.870

DOI： 10.2995/jacsurg.35.687_references_DOI_FwXyBs0UR0OmxLC7jslD5qKShED

CiNii Research

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器内視鏡学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本臨床外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本臨床外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本臨床外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本肺癌学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本臨床外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器内視鏡学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本臨床外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本臨床外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本肺癌学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本肺癌学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本臨床外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本肺癌学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器外科学会  

Other Link:： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2019&ichushi_jid=J02256&link_issn=&doc_id=20190123480007&doc_link_id=1390001288107566848&url=https%3A%2F%2Fcir.nii.ac.jp%2Fcrid%2F1390001288107566848&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_3.gif

Ichushi

researchmap

J-GLOBAL

researchmap

Language：Japanese   Publisher：北海道外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本内視鏡外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本内視鏡外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本内視鏡外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本内視鏡外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本内視鏡外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本内視鏡外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本臨床外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本臨床外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本肺癌学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本臨床外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本臨床外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：北海道外科学会  

Other Link:： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2018&ichushi_jid=J01375&link_issn=&doc_id=20180712130001&doc_link_id=%2Fdc7hksrg%2F2018%2F006301%2F002%2F0002-0005%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdc7hksrg%2F2018%2F006301%2F002%2F0002-0005%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本臨床外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本肺癌学会  

Ichushi

researchmap

Language：Japanese   Publisher：北海道外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：北海道外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本肺癌学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本内視鏡外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本臨床外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：北海道外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器内視鏡学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本内視鏡外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本肺癌学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本臨床外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器外科学会  

Ichushi

researchmap